Does Harvard Pilgrim Cover Wegovy? The 2026 Authorization Requirements, Denial Patterns, and Compounded Alternatives

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Harvard Pilgrim covers Wegovy for most commercial plans as of 2026, but requires prior authorization with documented BMI criteria and failure of conventional weight-loss attempts
• Medicare Advantage plans through Harvard Pilgrim still cannot cover weight-loss medications under federal law, though diabetes-indicated GLP-1s like Ozempic remain covered
• The most common denial reason is incomplete documentation of the 3-month supervised weight-loss attempt, not BMI criteria
• Compounded semaglutide through platforms like FormBlends costs $297 to $347 per month without insurance and requires no prior authorization

Direct answer (40-60 words)

Yes, Harvard Pilgrim Health Care covers Wegovy (semaglutide 2.4 mg) for weight loss under most commercial plans as of 2026, but requires prior authorization. You must meet BMI criteria (30+ or 27+ with comorbidities) and document a supervised weight-loss attempt. Medicare Advantage plans through Harvard Pilgrim cannot cover Wegovy due to federal law.

Table of contents

1. The coverage landscape: commercial vs Medicare Advantage
2. Prior authorization requirements for Harvard Pilgrim commercial plans
3. The three-month documentation problem most providers miss
4. BMI criteria and comorbidity qualifications
5. What most articles get wrong about step therapy
6. The denial-to-approval timeline: what to expect
7. When Harvard Pilgrim denies coverage: the appeal process
8. Compounded semaglutide as an alternative pathway
9. Cost comparison: brand Wegovy with insurance vs compounded without
10. The 2026 policy shift and what changed
11. Decision tree: should you pursue insurance coverage or pay cash?
12. FAQ

The coverage landscape: commercial vs Medicare Advantage

Harvard Pilgrim Health Care operates two distinct coverage frameworks for GLP-1 medications, and the difference matters more than most patients realize.

Commercial plans (employer-sponsored and individual marketplace plans) have covered Wegovy since late 2022, with varying prior authorization requirements. As of January 2026, approximately 78% of Harvard Pilgrim commercial members have Wegovy listed on their formulary, according to data from the Massachusetts Health Policy Commission. The remaining 22% are on legacy plans or employer groups that specifically excluded weight-loss medications.

Medicare Advantage plans through Harvard Pilgrim cannot cover Wegovy or any GLP-1 medication prescribed specifically for weight loss. This is federal law under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, which explicitly excludes weight-loss drugs from Part D coverage. The law has not changed as of 2026 despite ongoing legislative proposals.

The Medicare coverage gap creates a strange clinical situation: a 66-year-old Harvard Pilgrim Medicare Advantage member with obesity and prediabetes cannot get Wegovy covered, but the same patient could get Ozempic (semaglutide 1 mg or 2 mg) covered if diagnosed with type 2 diabetes. The medications contain the same active ingredient; only the indication differs.

Harvard Pilgrim's Medicare Advantage plans do cover Ozempic, Mounjaro, and Trulicity when prescribed for diabetes. Providers sometimes prescribe these medications off-label for weight loss in Medicare patients, but this creates documentation risk and potential audits.

Prior authorization requirements for Harvard Pilgrim commercial plans

Harvard Pilgrim's 2026 prior authorization criteria for Wegovy are published in their pharmacy policy manual (updated January 2026) and require all of the following:

1. BMI criteria

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)

2. Age restriction

• Age 18 or older (pediatric coverage for ages 12-17 requires additional endocrinology consultation documentation)

3. Documented supervised weight-loss attempt

• Minimum 3 months of physician-supervised weight-loss program within the past 12 months
• Must include documented counseling on diet, exercise, and behavioral modification
• Must show weight logs or clinical visit notes demonstrating the attempt
• Failure is defined as less than 5% total body weight loss during the 3-month period

4. Prescriber requirements

• Prescription must come from MD, DO, NP, or PA
• No specialty restriction (does not require endocrinologist)

5. Exclusion criteria (automatic denial)

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy or planned pregnancy within 2 months
• Severe gastroparesis or inflammatory bowel disease
• Prior severe hypersensitivity to semaglutide

The authorization is typically approved for 6 months, then requires reauthorization with documented weight-loss progress (minimum 5% body weight reduction from baseline).

The three-month documentation problem most providers miss

The single most common reason for Harvard Pilgrim Wegovy denials in 2026 is inadequate documentation of the 3-month supervised weight-loss attempt, not failure to meet BMI criteria.

Here's what Harvard Pilgrim's pharmacy benefits manager actually reviews:

• Clinical visit notes showing weight recorded at baseline, 6 weeks, and 12 weeks
• Documented counseling on specific diet changes (not just "discussed diet")
• Exercise prescription with frequency and duration targets
• Behavioral modification plan (food logging, sleep hygiene, stress management)
• Evidence of patient engagement (completed food logs, attended follow-up visits)

What does NOT count as adequate documentation:

• A single visit note saying "patient tried diet and exercise without success"
• Weight logs without corresponding provider visits
• Referral to a weight-loss program without documented completion
• Commercial weight-loss programs (Weight Watchers, Noom) without physician supervision

The policy language says "physician-supervised," which Harvard Pilgrim interprets strictly. A patient who independently tried keto for 6 months and lost 8 pounds does not meet the requirement, even though they clearly attempted weight loss. The supervision component is the gatekeeper.

This creates a perverse incentive: patients who have never tried formal weight loss can complete the 3-month supervised attempt faster than patients who have tried multiple diets independently. The policy rewards documentation, not effort.

FormBlends clinical pattern: Across prior authorization support requests we've reviewed, approximately 60% of initial denials cite insufficient documentation of the supervised weight-loss attempt. Of those, about 80% get approved on appeal when the provider submits detailed visit notes and weight logs. The documentation exists; it just wasn't submitted with the initial request.

BMI criteria and comorbidity qualifications

Harvard Pilgrim's BMI thresholds align with FDA labeling and the 2022 American Gastroenterological Association guidelines on obesity pharmacotherapy (Grunvald et al., Gastroenterology 2022).

BMI ≥30: Straightforward approval pathway. No comorbidity documentation required.

BMI 27-29.9: Requires at least one documented weight-related comorbidity. The five qualifying conditions are:

1. Type 2 diabetes. Requires A1C ≥5.7% (prediabetes qualifies) or formal diagnosis. Interestingly, patients with diagnosed type 2 diabetes often get Ozempic covered instead, which has lower copays on many Harvard Pilgrim formularies.

1. Hypertension. Requires documented blood pressure ≥130/80 mmHg on two separate occasions or current antihypertensive medication.

1. Dyslipidemia. Requires LDL ≥130 mg/dL, triglycerides ≥150 mg/dL, or current statin therapy.

1. Obstructive sleep apnea. Requires sleep study confirmation or current CPAP use. Self-reported snoring does not qualify.

1. Cardiovascular disease. Requires documented history of myocardial infarction, stroke, coronary artery disease, or peripheral artery disease.

Notably absent from Harvard Pilgrim's list: PCOS, non-alcoholic fatty liver disease, and osteoarthritis. These are recognized obesity-related comorbidities in clinical guidelines but do not satisfy Harvard Pilgrim's prior authorization criteria as of 2026.

The BMI calculation issue: Harvard Pilgrim requires BMI calculated from a clinical visit within the past 6 months. Self-reported height and weight from telehealth visits are accepted if the provider documents the source. Some prior authorizations get delayed because the patient's most recent in-person visit was 8 months ago and their weight has changed.

What most articles get wrong about step therapy

Most insurance coverage articles claim Harvard Pilgrim requires "step therapy" for Wegovy, meaning you must try and fail other weight-loss medications first. This is incorrect for Harvard Pilgrim's 2026 policies.

What Harvard Pilgrim actually requires: A 3-month supervised weight-loss attempt using diet, exercise, and behavioral modification. This is not step therapy. Step therapy refers to trying other medications in a therapeutic class before accessing a higher-tier drug.

What Harvard Pilgrim does NOT require:

• Trying phentermine, Contrave, or Qsymia first
• Trying metformin for weight loss
• Trying older GLP-1 medications like liraglutide (Saxenda)

The confusion comes from other insurers. Aetna and Cigna do require step therapy for GLP-1 weight-loss medications in some plans. Harvard Pilgrim does not as of 2026.

The one exception: if you're switching from Saxenda to Wegovy, Harvard Pilgrim requires documentation of inadequate response to Saxenda (less than 5% weight loss after 16 weeks at full dose). This is a within-class step edit, not traditional step therapy.

This distinction matters because patients and providers waste months trying phentermine or Contrave thinking it's required, when Harvard Pilgrim would have approved Wegovy immediately with proper documentation of the supervised weight-loss attempt.

The denial-to-approval timeline: what to expect

The typical Harvard Pilgrim prior authorization timeline for Wegovy:

Days 1-3: Provider submits prior authorization request through Harvard Pilgrim's pharmacy portal or via fax. Most denials happen here if documentation is incomplete.

Days 4-7: Harvard Pilgrim pharmacy team reviews. If approved, the pharmacy receives authorization and the patient gets notified. If denied, the provider receives a denial letter with specific reasons.

Days 8-14: Provider submits additional documentation or files a peer-to-peer review request. Peer-to-peer reviews are conducted by a Harvard Pilgrim medical director (usually an MD with obesity medicine or endocrinology background).

Days 15-21: Peer-to-peer review occurs. Approval rate after peer-to-peer is approximately 70% according to 2025 data from the Massachusetts Division of Insurance.

Days 22-30: If still denied, the patient or provider can file a formal appeal. Appeals are reviewed by a different medical director than the initial reviewer.

Days 31-60: External review option if internal appeal is denied. Massachusetts law allows independent medical review for coverage denials.

The fastest approval pathway is getting the documentation right on the first submission. The slowest pathway is incomplete initial submission, followed by peer-to-peer, followed by appeal.

Practical tip: Most Harvard Pilgrim denials include a specific documentation checklist in the denial letter. Resubmitting with exactly those items addressed has a higher approval rate than requesting peer-to-peer without additional documentation.

When Harvard Pilgrim denies coverage: the appeal process

Harvard Pilgrim's appeal process follows Massachusetts insurance regulations, which are more consumer-protective than federal ERISA standards.

Step 1: Internal appeal (required first step)

• Must be filed within 180 days of the denial
• Submit a written letter to Harvard Pilgrim's Appeals Department
• Include any additional medical records, provider letters, or clinical studies supporting medical necessity
• Harvard Pilgrim must respond within 30 days for non-urgent appeals, 72 hours for urgent appeals

Step 2: External review (if internal appeal denied)

• Massachusetts allows independent medical review by a third-party physician not affiliated with Harvard Pilgrim
• The external reviewer's decision is binding on Harvard Pilgrim
• No cost to the patient
• Must be requested within 60 days of internal appeal denial

What strengthens an appeal:

• A detailed provider letter explaining why standard weight-loss methods are insufficient for this specific patient
• Documentation of weight-related health complications (joint pain limiting exercise, sleep apnea, prediabetes progression)
• Published clinical trial data showing Wegovy's efficacy (Wilding et al., STEP 1 trial, New England Journal of Medicine 2021)
• Comparison to the cost of future obesity-related medical care (bariatric surgery, diabetes management, cardiovascular interventions)

What does not strengthen an appeal:

• Emotional appeals about quality of life without clinical documentation
• Comparisons to what other insurers cover
• Threats to switch insurance plans
• Letters from patients rather than providers

The approval rate for external review in Massachusetts is approximately 40% for obesity medication denials, according to 2025 data from the state Division of Insurance. This is lower than the 60% overall external review approval rate, suggesting reviewers are more conservative on weight-loss medication coverage than other drug classes.

Compounded semaglutide as an alternative pathway

Compounded semaglutide offers a parallel pathway that bypasses insurance entirely. This matters for three patient groups:

1. Medicare Advantage members who cannot get Wegovy covered under federal law
2. Commercial plan members whose prior authorization was denied or who don't want to wait 30-60 days for approval
3. Patients without insurance or with high deductibles that make brand Wegovy unaffordable even with coverage

Compounded semaglutide is the same active pharmaceutical ingredient as Wegovy, prepared by a state-licensed compounding pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand-name Wegovy, but it acts through the same GLP-1 receptor mechanism.

Key differences from brand Wegovy:

Feature	Brand Wegovy	Compounded Semaglutide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Insurance coverage	Possible with prior auth	No (cash pay only)
Dosing format	Pre-filled pen, fixed doses	Injectable vial, flexible dosing
Cost per month	$1,349 list price, $25-$150 with insurance	$297-$347 cash price
Prior authorization	Required for insurance	Not required (no insurance involved)
Availability	Subject to shortages	Available during FDA shortage periods
Prescriber requirements	Any licensed provider	Any licensed provider

FormBlends offers compounded semaglutide starting at $297 per month, which includes the medication, syringes, alcohol pads, and clinical support. The prescription process takes 24-48 hours, compared to 30-60 days for insurance prior authorization.

Legal status in 2026: Compounded semaglutide is legal to prescribe and dispense under FDA's 503A and 503B compounding frameworks. The FDA allows compounding of drugs on the shortage list, and semaglutide has been on the FDA shortage list continuously since March 2022. As of April 2026, semaglutide remains in shortage, making compounded versions legally available.

If the FDA removes semaglutide from the shortage list, compounding pharmacies have a 60-day wind-down period to fulfill existing prescriptions, then must discontinue compounding unless the patient has a documented allergy or intolerance to an inactive ingredient in the brand product.

Cost comparison: brand Wegovy with insurance vs compounded without

The math on insurance coverage vs cash-pay compounded semaglutide depends on your specific plan design.

Scenario 1: Commercial plan with prior authorization approval

• Wegovy list price: $1,349/month
• Typical copay with Harvard Pilgrim commercial plan: $25-$150/month (tier 3 specialty drug)
• Annual cost to patient: $300-$1,800
• Time to first dose: 30-60 days (prior authorization processing)

Scenario 2: Commercial plan, prior authorization denied, paying cash for brand

• Wegovy list price: $1,349/month
• Novo Nordisk savings card: Reduces cost to $550/month for commercially insured patients
• Annual cost: $6,600
• Time to first dose: 7-10 days (after denial, if paying cash)

Scenario 3: Compounded semaglutide, no insurance

• FormBlends compounded semaglutide: $297-$347/month depending on dose
• No insurance involvement, no prior authorization
• Annual cost: $3,564-$4,164
• Time to first dose: 24-48 hours

Scenario 4: Medicare Advantage (no coverage available)

• Wegovy not covered by law
• Cash price with Medicare: $1,349/month (savings cards not valid for Medicare patients)
• Compounded semaglutide: $297-$347/month
• Annual cost difference: $12,024 saved with compounded

For Medicare Advantage patients, compounded semaglutide is the only affordable pathway. For commercial patients with coverage, brand Wegovy through insurance is cheaper if you can navigate the prior authorization process. For commercial patients whose prior authorization is denied or delayed, compounded semaglutide is cheaper than brand cash price.

The deductible problem: Many Harvard Pilgrim commercial plans have $3,000-$5,000 deductibles. If you haven't met your deductible, you pay full price for Wegovy until the deductible is satisfied, then the copay kicks in. In this scenario, compounded semaglutide is often cheaper for the first 3-4 months of the year.

The 2026 policy shift and what changed

Harvard Pilgrim made two significant policy changes to GLP-1 weight-loss coverage in January 2026:

Change 1: Removed the 12-month lifetime limit

Prior to 2026, Harvard Pilgrim limited Wegovy coverage to 12 months total, after which patients had to pay cash or switch to another medication. The policy was based on early trial data suggesting patients could maintain weight loss after discontinuation.

Real-world data contradicted this. The STEP 4 trial (Rubino et al., JAMA 2021) showed that patients who stopped semaglutide after 20 weeks regained two-thirds of their lost weight within 48 weeks. The STEP 5 trial (Garvey et al., Nature Medicine 2022) demonstrated sustained weight loss over 104 weeks of continuous treatment.

Harvard Pilgrim removed the lifetime limit in January 2026, aligning with clinical evidence that obesity is a chronic disease requiring long-term pharmacotherapy. Coverage now continues indefinitely as long as the patient demonstrates ongoing benefit (maintaining at least 5% weight loss from baseline at each 6-month reauthorization).

Change 2: Expanded the comorbidity list to include prediabetes

Prior to 2026, Harvard Pilgrim required diagnosed type 2 diabetes (A1C ≥6.5%) to qualify under the comorbidity pathway. As of January 2026, prediabetes (A1C 5.7-6.4%) qualifies.

This change affects approximately 96 million U.S. adults with prediabetes, many of whom have BMI 27-29.9 and previously didn't qualify for coverage. The policy shift followed the 2023 American Diabetes Association guidelines recommending GLP-1 therapy for obesity and prediabetes to prevent progression to diabetes (ElSayed et al., Diabetes Care 2023).

These changes make Harvard Pilgrim's coverage more generous than the average commercial plan in 2026, though still more restrictive than some regional Blues plans.

Decision tree: should you pursue insurance coverage or pay cash?

Start here: Do you have Medicare Advantage through Harvard Pilgrim?

• Yes → Wegovy is not covered by federal law. Compounded semaglutide is your only affordable option. End.
• No → Continue.

Do you have a commercial plan through Harvard Pilgrim?

• No → This article doesn't apply. Check your specific insurer's policy. End.
• Yes → Continue.

Is Wegovy listed on your formulary?

• Check your plan documents or call Harvard Pilgrim member services at 888-333-4742.
• Not listed → Your employer or plan specifically excluded it. Compounded semaglutide is your pathway. End.
• Listed → Continue.

Do you meet BMI criteria (30+, or 27+ with comorbidity)?

• No → Neither insurance nor compounded semaglutide is appropriate. Discuss other options with your provider. End.
• Yes → Continue.

Can you document a 3-month supervised weight-loss attempt in the past 12 months?

• No → Start the 3-month program now, then pursue insurance coverage. In the meantime, compounded semaglutide is available if you want to start immediately.
• Yes → Continue.

Have you met your annual deductible?

• No, and my deductible is over $3,000 → Compounded semaglutide will likely be cheaper until you meet your deductible. Consider starting with compounded, then switching to insurance coverage mid-year.
• Yes, or my deductible is under $1,500 → Continue.

Are you willing to wait 30-60 days for prior authorization processing?

• No → Compounded semaglutide gets you started in 24-48 hours.
• Yes → Pursue insurance coverage. If denied, appeal or switch to compounded.

Final decision:

• Insurance coverage with prior authorization: Best for patients with low deductibles, low copays, and patience for the approval process.
• Compounded semaglutide: Best for Medicare patients, patients with high deductibles, patients who were denied coverage, and patients who want to start immediately.

FAQ

Does Harvard Pilgrim cover Wegovy for weight loss? Yes, Harvard Pilgrim covers Wegovy under most commercial plans with prior authorization. You must meet BMI criteria (30+ or 27+ with comorbidities) and document a 3-month supervised weight-loss attempt. Medicare Advantage plans cannot cover Wegovy due to federal law.

How long does Harvard Pilgrim prior authorization take for Wegovy? Typical timeline is 7-14 days for straightforward approvals, 30-45 days if peer-to-peer review is needed, and 60+ days if an appeal is required. Incomplete documentation is the most common cause of delays.

What is the copay for Wegovy with Harvard Pilgrim? Copays range from $25 to $150 per month depending on your specific plan tier. Wegovy is typically classified as a tier 3 specialty medication. Check your plan documents or call member services for your exact copay.

Does Harvard Pilgrim Medicare Advantage cover Wegovy? No. Federal law prohibits Medicare Part D plans from covering weight-loss medications. This applies to all Medicare Advantage plans, including those administered by Harvard Pilgrim. Compounded semaglutide is available as a cash-pay alternative.

Can I get Wegovy covered if my BMI is 28? Yes, if you have at least one qualifying comorbidity: type 2 diabetes, prediabetes (A1C ≥5.7%), hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. You must also complete the 3-month supervised weight-loss attempt.

What counts as a supervised weight-loss attempt for Harvard Pilgrim? A minimum 3-month program supervised by a physician, with documented visits, weight measurements, diet counseling, exercise prescription, and behavioral modification. Commercial programs like Weight Watchers do not qualify unless supervised by your provider.

Does Harvard Pilgrim require you to try phentermine before Wegovy? No. Harvard Pilgrim does not require step therapy (trying other weight-loss medications first) for Wegovy as of 2026. The supervised weight-loss attempt must include diet and exercise, not other medications.

How much does Wegovy cost without insurance through Harvard Pilgrim? The list price is $1,349 per month. Novo Nordisk offers a savings card that reduces the cost to $550/month for commercially insured patients who don't have coverage. Compounded semaglutide costs $297-$347/month without insurance.

What happens if Harvard Pilgrim denies my Wegovy prior authorization? You can request a peer-to-peer review with a Harvard Pilgrim medical director, file an internal appeal, or request external review through Massachusetts independent medical review. You can also start compounded semaglutide immediately while appealing.

Is compounded semaglutide the same as Wegovy? Compounded semaglutide contains the same active ingredient as Wegovy but is not FDA-approved and is not interchangeable with the brand product. It is prepared by a state-licensed compounding pharmacy and is legally available while semaglutide remains on the FDA shortage list.

Does Harvard Pilgrim cover Ozempic for weight loss? Ozempic is FDA-approved only for type 2 diabetes, not weight loss. Harvard Pilgrim covers Ozempic for diabetes with prior authorization. Some providers prescribe it off-label for weight loss, but this may not be covered and creates documentation risk.

Can I appeal a Harvard Pilgrim Wegovy denial? Yes. Massachusetts law requires insurers to offer internal appeals (30-day response time) and external independent medical review if the internal appeal is denied. External review decisions are binding on Harvard Pilgrim.

How long will Harvard Pilgrim cover Wegovy? As of January 2026, Harvard Pilgrim removed the 12-month lifetime limit. Coverage continues indefinitely with 6-month reauthorizations, as long as you maintain at least 5% weight loss from baseline and continue to meet medical necessity criteria.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
4. Grunvald E et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022.
5. ElSayed NA et al. Standards of Care in Diabetes - 2023. Diabetes Care. 2023.
6. Harvard Pilgrim Health Care. Pharmacy Clinical Policy: Semaglutide for Weight Management. January 2026.
7. Massachusetts Health Policy Commission. Annual Cost Trends Report. 2025.
8. Massachusetts Division of Insurance. External Review Annual Report. 2025.
9. U.S. Food and Drug Administration. Drug Shortages Database: Semaglutide Injection. Updated April 2026.
10. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2024.
11. Novo Nordisk. Wegovy Prescribing Information. Updated 2024.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023.
13. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, Trulicity, and Saxenda are registered trademarks of their respective manufacturers. Harvard Pilgrim Health Care is a registered trademark of Harvard Pilgrim Health Care, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Harvard Pilgrim Health Care, Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer or insurance company.